December 20, 2024 11:08 AM EST

Sofinnova outlines $550M fund after IPOs and M&A deals

Kyle LaHucik

Senior Reporter

Sofinnova Investments, one of the longest-standing biotech investment firms, has penciled in plans for a new $550 million fund, Endpoints News has learned.

The Menlo …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sofinnova outlines $550M fund after IPOs and M&A deals

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

'No miracles': What Regeneron's George Yancopoulos really thinks of AI

GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?

China's biotech boom is threatening US drugmakers' dominance

J&J’s Spravato hit $1B in revenue in 2024

Inhibrx’s early colorectal cancer data clouded by patient death

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

'No mir­a­cles': What Re­gen­eron's George Yan­copou­los re­al­ly thinks of AI

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

J&J’s Spra­va­to hit $1B in rev­enue in 2024

In­hi­brx’s ear­ly col­orec­tal can­cer da­ta cloud­ed by pa­tient death

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

Sofinnova outlines $550M fund after IPOs and M&A deals

'No miracles': What Regeneron's George Yancopoulos really thinks of AI

GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?

China's biotech boom is threatening US drugmakers' dominance

J&J’s Spravato hit $1B in revenue in 2024

Inhibrx’s early colorectal cancer data clouded by patient death

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach